Contract manufacturing Major Players in the Medical Device Outsourcing Market
■Cardinal Health ■Jabil ■Heraeus Holding ■Flex ■TE Connectivity ■Sanmina ■Celestica
Source: Valuates Reports
■SGS SA ■Eurofins Scientific ■Intertek Group ■PPD ■Tecomet ■Integer ■Wuxi Apptec
products or processes best, while keeping an OEM’s own core competencies close.
What were the main drivers behind the increased use of CDMO/CMOs? The main drivers behind the evolution in using CDMO/CMO in the medical device industry are the same as most other industries: cost reduction, focus on core competencies, and enablement of growth and flexibility.
The Medical Device Outsourcing market size is estimated to be valued at $7.42bn in 2021 and projected to reach $143bn by 2028, recording a compound annual growth rate of 9.7%. Major producers in the sector include Cardinal Health, Jabil, and Heraeus Holding, which accounted for 15.52%, 9.03%, and 8.17% of revenue in 2019. The medical device outsourcing market is expected to grow in response to the need to reduce time to market. Rapid time-to-market (TTM), time-to-volume (TTV), and time-to-profit (TTP) are critical for manufacturer competitiveness and customer satisfaction in the
medical device industry. Source: Valuates Reports
engineering talent, and management that strives to use that talent to add more value for customers. Ultimately, partnering with customers in Design for Manufacturing (DFM) leads to partnering on actual product design. This trend is no different in medical device manufacturing, however, with more extensive quality and regulations the trend is more conservative and adoption is slower than other industries.
How has the shift toward development changed the core competencies outsourcing partners need to be valuable assets to OEMs? Outsourcing partners for medical technology need to develop not only manufacturing technologies as core competencies, but they need to mirror the capabilities of the OEM with regards to understanding therapeutic needs, ability to align product designs to medical customer needs, and be able to support product life cycles from concept to design and approval. In other words, the CDMO needs to become a full extension of the OEM customer with regards to core competencies.
Has this shift from in-house to outsourced or collaborative product design resulted in cost savings for medical device companies? I expect there are many instances where outsourcing has resulted in cost savings, especially where high labour content processes and products are transferred to low-cost countries. However, outsourcing is a much more complex formula than just cost reduction and is a strategy that also enables innovation through placing products and processes where capabilities match the
44
The medical device industry is likely lagging behind other industries in adopting this philosophy, primarily due to the critical nature of the products and need to control quality. As pressures to be more efficient and cost effective have emerged in the health care systems in the past two decades, they have also driven the capabilities available at the CDMO/CMOs and increased trust in the quality systems at outsource suppliers.
Has the move to outsourcing brought benefits to patients? If so, how? Setting up the best supply chains, whether insource or outsource, benefits the patients through quality, reliability, and value. When outsourcing also allows OEMs to focus on core competencies, the innovation is also enabled and benefits the patients with better products to support better health. Outsourcing and CDMO/CMO capabilities also allow innovative ideas from inventors to be realised into products without needing manufacturing infrastructure. All these factors benefit the patients.
Do you expect to see a further evolution in the relationships between the medical device industry and CDMO/CMOs?
Closer relationships between OEM’s and CDMO/CMO can only lead to better placement of development, products, and processes in the optimal places in the supply chain. While the industry will continue to be protective of core competencies and intellectual property, non-core processes and products will trend toward outsourcing.
To what extent will these changes (if any) be prompted by the pandemic experience?
Global industries have experienced the impact of supply chain disruption on performance and delivery to customers. The medical device industry is no exception. In my opinion, with the continued advancement of manufacturing automation I envisage manufacturing leaning toward more localisation, and also being closer to the distribution centres and customers. ●
Medical Device Developments /
www.nsmedicaldevices.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128
